ALKS Alkermes plc Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

ALKS [NASD]

Alkermes plc

Healthcare | Biotechnology | Ireland

statements

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	0.70%	Shs Outstand	158.10M	Perf Week	0.51%
Market Cap	3.15B	Forward P/E	46.11	EPS next Y	0.43	Insider Trans	-27.13%	Shs Float	157.21M	Perf Month	17.27%
Income	-138.90M	PEG	-	EPS next Q	-0.02	Inst Own	96.66%	Short Float	7.28%	Perf Quarter	27.61%
Sales	1.19B	P/S	2.64	EPS this Y	-39.40%	Inst Trans	4.00%	Short Ratio	7.26	Perf Half Y	2.50%
Book/sh	6.72	P/B	2.93	EPS next Y	2250.00%	ROA	-7.80%	Target Price	19.09	Perf Year	-14.17%
Cash/sh	3.10	P/C	6.36	EPS next 5Y	24.00%	ROE	-12.90%	52W Range	11.98 - 25.35	Perf YTD	-3.48%
Dividend	-	P/FCF	-	EPS past 5Y	-43.30%	ROI	-12.80%	52W High	-22.33%	Beta	1.48
Dividend %	-	Quick Ratio	2.40	Sales past 5Y	13.60%	Gross Margin	84.70%	52W Low	64.36%	ATR	0.80
Employees	2235	Current Ratio	2.70	Sales Q/Q	10.40%	Oper. Margin	-11.50%	RSI (14)	62.30	Volatility	3.70% 4.90%
Optionable	Yes	Debt/Eq	0.26	EPS Q/Q	60.30%	Profit Margin	-11.60%	Rel Volume	0.69	Prev Close	20.04
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Apr 29 BMO	Payout	-	Avg Volume	1.58M	Price	19.69
Recom	2.90	SMA20	5.75%	SMA50	16.17%	SMA200	8.77%	Volume	1,084,617	Change	-1.75%

Feb-14-20

Reiterated

H.C. Wainwright

Neutral

$26 → $25

Feb-14-20

Downgrade

JP Morgan

Overweight → Neutral

$21

Feb-14-20

Downgrade

BofA/Merrill

Buy → Neutral

$31 → $20

Feb-06-20

Initiated

Mizuho

Neutral

Jan-31-20

Upgrade

Wolfe Research

Underperform → Peer Perform

Sep-05-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

$30 → $20

Jul-15-19

Upgrade

Goldman

Sell → Neutral

May-31-19

Initiated

H.C. Wainwright

Neutral

May-01-19

Downgrade

Citigroup

Buy → Neutral

Dec-19-18

Downgrade

Goldman

Neutral → Sell

Dec-14-18

Initiated

Wolfe Research

Underperform

Dec-13-18

Downgrade

Credit Suisse

Outperform → Underperform

Nov-05-18

Initiated

Piper Jaffray

Neutral

$40

Aug-07-18

Initiated

Stifel

Hold

$15 → $45

Jun-21-18

Downgrade

Morgan Stanley

Equal-Weight → Underweight

Jun-06-18

Initiated

B. Riley FBR, Inc.

Buy

$60

May-16-18

Upgrade

Citigroup

Neutral → Buy

May-11-18

Initiated

BofA/Merrill

Buy

$56

Apr-02-18

Downgrade

Evercore ISI

Outperform → In-line

Feb-22-18

Downgrade

Jefferies

Buy → Hold

Jun-30-20 09:36AM	Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? Zacks
Jun-29-20 07:00AM	Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program PR Newswire
Jun-24-20 07:00AM	Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities PR Newswire
Jun-22-20 09:01AM	New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II PR Newswire
Jun-19-20 06:04PM	Alzheimer's Drug Approval More Critical for Biogen After Patent Decision GuruFocus.com
Jun-16-20 07:28AM	Edited Transcript of ALKS earnings conference call or presentation 29-Apr-20 12:00pm GMT Thomson Reuters StreetEvents +5.27%
Jun-12-20 09:11AM	Should You Avoid Alkermes Plc (ALKS)? Insider Monkey
Jun-08-20 09:04AM	How Alkermes (ALKS) Stock Stands Out in a Strong Industry Zacks
Jun-04-20 04:00PM	Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference PR Newswire
May-29-20 11:31AM	Alkermes (ALKS) Up 21.6% Since Last Earnings Report: Can It Continue? Zacks
May-27-20 07:00AM	Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting PR Newswire
May-20-20 07:00AM	Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia PR Newswire
May-14-20 07:00AM	Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society PR Newswire
May-11-20 07:00AM	Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis PR Newswire
May-06-20 04:00PM	Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference PR Newswire
May-01-20 09:45AM	Analysts Have Lowered Expectations For Alkermes plc (NASDAQ:ALKS) After Its Latest Results Simply Wall St.
Apr-30-20 11:12AM	Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat Zacks
Apr-29-20 03:00PM	Alkermes PLC (ALKS) Q1 2020 Earnings Call Transcript Motley Fool -10.59%
07:47AM	Alkermes: Q1 Earnings Insights Benzinga
07:00AM	Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update PR Newswire
Apr-28-20 11:58AM	What's in Store for Innoviva (INVA) This Earnings Season? Zacks
11:40AM	ANIK vs. ALKS: Which Stock Should Value Investors Buy Now? Zacks
Apr-22-20 04:00PM	Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results PR Newswire
08:49AM	Why Alkermes (ALKS) Might Surprise This Earnings Season Zacks
07:00AM	Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer PR Newswire
Apr-16-20 12:31PM	Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-04-20 10:02AM	Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly? Simply Wall St.
Mar-29-20 10:25PM	Here is What Hedge Funds Think About Alkermes Plc (ALKS) Insider Monkey
Mar-26-20 02:53PM	The Top 10 Biotechnology Companies Investopedia
Mar-14-20 11:30AM	Alkermes (ALKS) Down 8.6% Since Last Earnings Report: Can It Rebound? Zacks
Mar-04-20 07:00AM	Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia PR Newswire
Feb-28-20 05:32AM	The Independent Director of Alkermes plc (NASDAQ:ALKS), Nancy Wysenski, Just Bought 161% More Shares Simply Wall St. +6.16%
Feb-24-20 04:00PM	Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference PR Newswire
02:08PM	Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' sr. secured term loan; stable outlook Moody's
Feb-19-20 04:01PM	Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference PR Newswire +6.02%
Feb-18-20 11:18PM	Edited Transcript of ALKS earnings conference call or presentation 13-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-14-20 10:49AM	Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4 Zacks
10:46AM	Alkermes Reported More Revenue Than Expected. Heres Why the Stock Is Falling. Barrons.com
Feb-13-20 09:32AM	Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat Estimates Zacks -7.59%
09:05AM	Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates Zacks
08:05AM	The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Benzinga
07:00AM	Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020 PR Newswire
05:00AM	Alkermes Targets Bipolar Disorder and Schizophrenia MoneyShow
Feb-10-20 09:28AM	Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 04:00PM	Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results PR Newswire
12:30PM	Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth Zacks
Jan-29-20 09:54AM	Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review Zacks
Jan-28-20 07:00AM	Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder PR Newswire
Jan-16-20 05:50PM	Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-13-20 09:40AM	Hedge Fund Favorites vs. Alkermes Plc (ALKS) In 2019 Insider Monkey
05:11AM	Does Alkermes plc (NASDAQ:ALKS) Have A High Beta? Simply Wall St.
Jan-10-20 05:50PM	Alkermes (ALKS) Gains As Market Dips: What You Should Know Zacks
Jan-08-20 04:00PM	Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-20 11:40AM	LGND vs. ALKS: Which Stock Is the Better Value Option? Zacks
Dec-30-19 10:23AM	Alnylam Stock Up More Than 61% YTD on Pipeline Progress Zacks
09:44AM	Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA Zacks
Dec-26-19 07:22AM	New Strong Buy Stocks for December 26th Zacks
Dec-24-19 01:12PM	Seattle Genetics Submits NDA to FDA for Tucatinib Combo Zacks
Dec-20-19 05:50PM	Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know Zacks
12:00PM	All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy Zacks
09:28AM	Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris Zacks
08:27AM	Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib Zacks
08:13AM	New Strong Buy Stocks for December 20th Zacks
Dec-19-19 08:59AM	5 Losing Stocks From 2019 to Rebound Next Year Zacks
Dec-18-19 08:50AM	Alnylam's Kidney Disease Drug Succeeds in Late Stage Study Zacks
07:59AM	5 Beaten-Down Biotech Stocks Set to Rebound in 2020 Zacks
Dec-17-19 10:25AM	Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis Zacks
09:59AM	The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora Zacks
Dec-16-19 03:55PM	5 Health Care Stocks Gurus Are Buying GuruFocus.com
09:46AM	Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote Zacks
08:06AM	These 5 Loser Stocks of 2019 Could be Big Winners in 2020 Zacks
08:05AM	Biogen's Gosuranemab Fails in Phase II Brain Disorder Study Zacks
Dec-13-19 08:33AM	Momenta Pharmaceuticals (MNTA) Catches Eye: Stock Jumps 7.1% Zacks
Dec-12-19 09:36AM	Amgen's Osteoporosis Drug Evenity Gets Approval in Europe Zacks
09:10AM	Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher Zacks
Dec-11-19 12:12PM	FDA told Alkermes to stop publishing Vivitrol ad MarketWatch
12:03PM	UPDATE 1-FDA issues warning letter to Alkermes over opioid addiction treatment ad Reuters
11:25AM	FDA issues warning letter to Alkermes over opioid addiction treatment ad Reuters
Dec-10-19 09:26AM	TG Therapeutics' Shares Soar on Positive Early-Stage Data Zacks
Dec-09-19 04:31PM	Regeneron Reports Initial Data for Multiple Myeloma Drug Zacks
04:03PM	bluebird Reports Positive Top-Line Data on Myeloma Drug Zacks
Dec-08-19 07:52AM	Should You Be Pleased About The CEO Pay At Alkermes plc's (NASDAQ:ALKS) Simply Wall St.
Dec-06-19 09:26AM	Sage Therapeutics' Depression Drug Fails in Study, Stock Down Zacks
09:17AM	Hedge Funds Are Warming Up To Alkermes Plc (ALKS) Insider Monkey
Dec-05-19 10:02AM	Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug Zacks
09:07AM	Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon Zacks
Dec-04-19 10:10AM	AstraZeneca Sells Schizophrenia Drug Rights in US and Canada Zacks
09:29AM	Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session Zacks
Dec-03-19 03:18PM	Epizyme Announces FDA Committee Review of Tazemetostat NDA Zacks
09:16AM	Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU Zacks
08:29AM	Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1% Zacks
Nov-29-19 09:26AM	Global Blood (GBT) in Focus: Stock Moves 5.2% Higher Zacks
09:13AM	BioDelivery's Belbuca Sales & Symproic Addition Encouraging Zacks
Nov-27-19 08:52AM	ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
Nov-26-19 08:36AM	Myovant (MYOV) Catches Eye: Stock Jumps 6.7% Zacks
08:24AM	Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
Nov-25-19 09:18AM	Alexion Gets Approval for Label Expansion of Soliris in Japan Zacks
07:00AM	Alkermes Completes Acquisition of Rodin Therapeutics PR Newswire
Nov-22-19 09:45AM	Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy Zacks
09:31AM	Alkermes (ALKS) Up 3% Since Last Earnings Report: Can It Continue? Zacks

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jun 07	Option Exercise	0.00	1,250	0	15,201	Jun 08 04:21 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 05	Option Exercise	0.00	3,500	0	3,500	Jun 08 04:19 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 14	Option Exercise	11.74	75,000	880,500	834,094	May 14 05:00 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	May 14	Option Exercise	11.74	21,983	258,080	91,828	May 14 04:58 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 14	Sale	15.00	75,000	1,125,233	759,094	May 14 05:00 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	May 13	Option Exercise	11.74	6,250	73,375	44,831	May 14 04:55 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	May 13	Sale	15.39	6,250	96,193	38,581	May 14 04:55 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 12	Option Exercise	11.74	18,000	211,320	219,822	May 14 04:54 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 12	Sale	15.75	18,000	283,469	201,822	May 14 04:54 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 07	Option Exercise	11.74	50,000	587,000	809,094	May 07 04:26 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 07	Sale	14.63	50,000	731,265	759,094	May 07 04:26 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 05	Option Exercise	11.74	25,000	293,500	226,822	May 07 04:25 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 05	Sale	14.06	25,000	351,425	201,822	May 07 04:25 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Apr 02	Option Exercise	11.74	50,000	587,000	809,094	Apr 03 04:22 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Apr 02	Sale	13.79	50,000	689,500	759,094	Apr 03 04:22 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 26	Option Exercise	11.74	75,000	880,500	834,094	Mar 26 04:38 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 26	Sale	14.36	75,000	1,077,225	759,094	Mar 26 04:38 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 24	Option Exercise	11.74	25,000	293,500	226,822	Mar 26 04:36 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 24	Sale	13.91	25,000	347,718	201,822	Mar 26 04:36 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 19	Option Exercise	11.74	75,000	880,500	834,094	Mar 19 04:10 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 19	Sale	14.47	75,000	1,085,428	759,094	Mar 19 04:10 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 17	Option Exercise	11.74	25,000	293,500	226,822	Mar 19 04:10 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 17	Sale	13.54	25,000	338,506	201,822	Mar 19 04:10 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Mar 02	Option Exercise	11.74	3,000	35,220	61,934	Mar 03 04:31 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 01	Option Exercise	0.00	17,500	0	766,864	Mar 03 04:36 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 01	Option Exercise	0.00	4,500	0	201,822	Mar 03 04:33 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Mar 01	Option Exercise	0.00	2,250	0	59,596	Mar 03 04:31 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Mar 01	Option Exercise	0.00	4,500	0	71,168	Mar 03 04:27 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Mar 01	Option Exercise	0.00	2,250	0	39,243	Mar 03 04:23 PM
Wysenski Nancy	Director	Feb 24	Buy	19.65	6,940	136,371	11,242	Feb 25 05:15 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Feb 21	Option Exercise	0.00	32,400	0	763,750	Feb 24 04:15 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Feb 21	Option Exercise	0.00	5,825	0	197,322	Feb 24 04:14 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 21	Option Exercise	0.00	6,875	0	15,955	Feb 24 04:13 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Feb 21	Option Exercise	0.00	6,875	0	59,362	Feb 24 04:12 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Feb 21	Option Exercise	0.00	5,825	0	68,380	Feb 24 04:11 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Feb 21	Option Exercise	0.00	4,800	0	38,384	Feb 24 04:10 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Feb 17	Option Exercise	0.00	8,750	0	735,236	Feb 18 04:12 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Feb 17	Option Exercise	0.00	3,000	0	191,497	Feb 18 04:11 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Feb 17	Option Exercise	0.00	2,500	0	53,253	Feb 18 04:09 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Feb 17	Option Exercise	0.00	3,000	0	63,459	Feb 18 04:07 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Feb 17	Option Exercise	0.00	2,500	0	34,452	Feb 18 04:05 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Feb 16	Option Exercise	0.00	18,125	0	734,558	Feb 18 04:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 16	Option Exercise	0.00	3,375	0	10,252	Feb 18 04:10 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Feb 16	Option Exercise	0.00	3,375	0	188,497	Feb 18 04:11 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Feb 16	Option Exercise	0.00	3,375	0	51,925	Feb 18 04:09 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Feb 16	Option Exercise	0.00	3,375	0	61,631	Feb 18 04:07 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Feb 16	Option Exercise	0.00	2,375	0	32,777	Feb 18 04:05 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Nov 14	Option Exercise	9.21	100,000	921,000	816,433	Nov 15 04:08 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Nov 14	Sale	19.50	100,000	1,950,000	716,433	Nov 15 04:08 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Nov 13	Option Exercise	9.21	20,000	184,200	205,122	Nov 15 04:07 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Nov 13	Sale	19.70	20,000	394,056	185,122	Nov 15 04:07 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Nov 08	Option Exercise	9.21	30,205	278,188	746,638	Nov 08 04:06 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Nov 08	Sale	19.73	30,205	595,827	716,433	Nov 08 04:06 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Nov 07	Option Exercise	9.21	69,795	642,812	786,228	Nov 08 04:06 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Nov 07	Sale	19.81	69,795	1,382,618	716,433	Nov 08 04:06 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Nov 06	Option Exercise	9.21	20,000	184,200	205,122	Nov 08 04:04 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Nov 06	Sale	19.76	20,000	395,116	185,122	Nov 08 04:04 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Sep 19	Option Exercise	9.21	100,000	921,000	816,433	Sep 23 06:16 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Sep 19	Sale	21.54	100,000	2,153,550	716,433	Sep 23 06:16 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Sep 13	Option Exercise	11.74	20,000	234,800	58,256	Sep 17 07:06 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Sep 12	Option Exercise	9.21	100,000	921,000	816,433	Sep 13 05:20 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Sep 12	Sale	22.68	100,000	2,268,220	716,433	Sep 13 05:20 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Sep 05	Option Exercise	9.21	100,000	921,000	816,433	Sep 06 05:01 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Sep 05	Sale	20.18	100,000	2,017,830	716,433	Sep 06 05:01 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience